American Cancer Society to Fund Studies on Checkpoint Inhibitors

 

 American Cancer Society  pic

American Cancer Society
Image: cancer.org

A Washington, DC-based real estate investment professional, Mohsen Grayeli serves as president of ASAP, LLC, a holding company he launched in 2003. Beyond his professional pursuits, Mohsen Grayeli gives back to the community by supporting several organizations, including the American Cancer Society (ACS).

In a recent press release, ACS announced that it has launched a partnership with the Melanoma Research Alliance (MRA) to fund studies focused on minimizing the side effects associated with checkpoint inhibitors. A promising class of immunotherapy drugs, checkpoint inhibitors help trigger an immune response that sends the body’s T-cells to attack cancer cells. The drugs were first used to treat melanoma and have since been approved for use on cancer types affecting several areas of the body.

Although many patients experience few issues with checkpoint inhibitors, they have led to serious side effects and even death in others. Through the new partnership, ACS and MRA will fund pilot projects that aim to maximize checkpoint inhibitors’ effectiveness while minimizing their toxicity.

The organizations have committed a combined $2 million to fund one study at $1 million and five additional research projects at $200,000 each. ACS and MRA expect to award the first grants in spring 2018.